THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • February 26th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledFebruary 26th, 2021 Company Industry JurisdictionTHIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made and entered into as of September 2, 2020, by and among (i) Finch Therapeutics Group, Inc., a Delaware corporation (the “Company”), (ii) each holder of Common Stock listed on Schedule A under the heading “Common Stockholders” (the “Existing Common Holders”), (iii) each holder of Series A Preferred Stock listed on Schedule A under the heading “Series A Stockholders” (the “Series A Preferred Holders”), (iv) each holder of Series B Preferred Stock listed on Schedule A under the heading “Series B Stockholders” (the “Series B Preferred Holders”), (v) each holder of Series C Preferred Stock listed on Schedule A under the heading “Series C Stockholders” (together with the Series A Preferred Holders and the Series B Preferred Holders, the “Existing Preferred Holders”), and (vi) each purchaser of Series D Preferred Stock (together with the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred
THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENTStockholders Agreement • February 9th, 2021 • Finch Therapeutics Group, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledFebruary 9th, 2021 Company Industry JurisdictionTHIS THIRD AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made and entered into as of September 2, 2020, by and among (i) Finch Therapeutics Group, Inc., a Delaware corporation (the “Company”), (ii) each holder of Common Stock listed on Schedule A under the heading “Common Stockholders” (the “Existing Common Holders”), (iii) each holder of Series A Preferred Stock listed on Schedule A under the heading “Series A Stockholders” (the “Series A Preferred Holders”), (iv) each holder of Series B Preferred Stock listed on Schedule A under the heading “Series B Stockholders” (the “Series B Preferred Holders”), (v) each holder of Series C Preferred Stock listed on Schedule A under the heading “Series C Stockholders” (together with the Series A Preferred Holders and the Series B Preferred Holders, the “Existing Preferred Holders”), and (vi) each purchaser of Series D Preferred Stock (together with the Series A Preferred Stock, Series B Preferred Stock, and Series C Preferred